Cytologic Dysplasia Occurring After Busulfan (Myleran⌖) Therapy
Authors: HOWARD N. WARD
Journal: Annals of Internal Medicine (1965)

Case Studies1 October 1965Cytologic Dysplasia Occurring After Busulfan (Myleran⌖) TherapyA Syndrome Resembling Adrenocortical Insufficiency and Atrophic BronchitisHOWARD N. WARD, M.D., NADYA KONIKOV, M.D., EDWARD H. REINHARD, M.D., F.A.C.P.HOWARD N. WARD, M.D.Search for more papers by this author, NADYA KONIKOV, M.D.Search for more papers by this author, EDWARD H. REINHARD, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-63-4-654 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn 1956 Marinho and Martins (1) first called attention to a syndrome resembling adrenocortical insufficiency that occurred after busulfan (Myleran⌖) therapy in two patients with chronic granulocytic leukemia. In 1961 Kyle, Schwartz, Oliner, and Dameshek (2) reported four patients with chronic granulocytic leukemia who developed a similar syndrome after long-term busulfan therapy. In all of Kyle's patients there were hyperpigmentation of the skin, excessive fatigue, weakness, weight loss, nausea, and occasional vomiting. However, no endocrine abnormality could be demonstrated by laboratory tests. Cytologic dysplasia may also occur after treatment with antileukemic agents as reported by Weston and Guin (3) in...References1. MARINHOMARTINS HMPC: 1-4 Dimetanosulfoniloxibutano (G. T. 41-Myleran) na terapeutica da leucemia mieloide cronica. Arq. Brasil. Med. 46: 161, 1956. MedlineGoogle Scholar2. KYLESCHWARTZOLINERDAMESHEK RARSHLW: A syndrome resembling adrenal cortical insufficiency associated with long term busulfan (Myleran⌖) therapy. Blood 18: 497, 1961. CrossrefMedlineGoogle Scholar3. WESTONGUIN JTGH: Epithelial atypias with chemotherapy in 100 acute childhood leukemias. Cancer 8: 179, 1955. CrossrefMedlineGoogle Scholar4. GURELIDENHAMROOT NSWSW: Cytologic dysplasia related to busulfan (Myleran⌖) therapy. Report of a case. Obstet. Gynec. 21: 466, 1963. Google Scholar5. NELSONANDREWS BMGA: Breast cancer and cytologic dysplasia in many organs after busulfan (Myleran⌖). Amer. J. Clin. Path. 42: 37, 1964. CrossrefMedlineGoogle Scholar6. KANDORIKURIMOTO FS: An experimental study on the chronic toxicity of Myleran⌖ and its influence upon the lens, endocrine glands and internal organs of rats. Acta Path. Jap. 10: 35, 1960. MedlineGoogle Scholar7. CALERO C: Hyperpigmentation of the skin in patients with busulfan (Myleran⌖) therapy. Arch. Med. Panamen. 12: 101, 1963. MedlineGoogle Scholar8. CASTLEMANMCNEELY BB: Case records of the Massachusetts General Hospital. New Eng. J. Med. 272: 95, 1965. MedlineGoogle Scholar9. OLINERSCHWARTZRUBIODAMESHEK HRFW: Interstitial pulmonary fibrosis following busulfan therapy. Amer. J. Med. 31: 134, 1961. CrossrefMedlineGoogle Scholar10. KOLLER PC: Comparative effect of alkylating agents on cellular morphology. Ann. NY Acad. Sci. 68: 783, 1958. CrossrefMedlineGoogle Scholar11. DIAMONDANDERSONMCCREADIE IMMSR: Transplacental transmission of busulfan (Myleran⌖) in a mother with leukemia. Production of fetal malformation and cytomegaly. Pediatrics 25: 85, 1960. MedlineGoogle Scholar12. WALLER U: Riesenkerne nach mylerantherapie und milzbestralung bei chronischer myeloischer leukaemie. Path. Microbiol. (Basel) 23: 283, 1960. MedlineGoogle Scholar13. FORNIKOSSGELLER AMLGW: Cytologic study of the effect of cyclophosphamide on the epithelium of the urinary bladder in man. Cancer 17: 1348, 1964. CrossrefMedlineGoogle Scholar14. KOSS LG: Diagnostic Cytology, J. B. Lippincott Co., Philadelphia, 1961. Google Scholar15. KOSS LG: Personal communication, 1964. Google Scholar16. MURPHYDELMOROLACON MLAC: Comparative effects of five polyfunctional alkylating agents on the rat fetus. Ann. NY Acad. Sci. 68: 762, 1958. CrossrefMedlineGoogle Scholar17. WALPOLE AL: Carcinogenic action of alkylating agents. Ibid., p. 750. Google Scholar18. SHIMKIN MG: Pulmonary tumor induction in mice with chemical agents used in the clinical management of lymphomas. Cancer 7: 410, 1954. CrossrefGoogle Scholar19. KOLLER PC: Dicentric chromosomes in a rat tumor induced by an aromatic nitrogen mustard. Heredity 6 (Suppl.): 181, 1953. Google Scholar20. STACEYCOBBCOUSENSALEXANDER KAMSFP: Reactions of the "radiomimetic" alkylating agents with macromolecules in vitro. Ann. NY Acad. Sci. 68: 682, 1958. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: HOWARD N. WARD, M.D.; NADYA KONIKOV, M.D.; EDWARD H. REINHARD, M.D., F.A.C.P.Affiliations: St. Louis, MissouriFrom the Departments of Medicine and Pathology, Washington University School of Medicine, and the Barnes Hospital, St. Louis, Mo.Dr. Ward was a Fellow in Hematology supported by grant 2 R10 CA 03376, U. S. Public Health Service, and the Barnes Hospital Clinical Research Unit is supported by grant FR-36, the General Research Centers Branch Division of Research Facilities and Resources, U. S. Public Health Service, Bethesda, Md.Requests for reprints should be addressed to Nadya Konikov, M.D., Division of Surgical Pathology, Barnes Hospital, St. Louis, Mo. 63110. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byEndocrinologic IssuesEffects of Therapy on Cytologic SpecimensEndocrine sequelae of cancer and cancer treatmentsToxicological review of busulfan (Myleran)Drug-Induced Interstitial Lung DiseasesMucocutaneous side effects of cancer chemotherapyDie chronische myeloische LeukämieCytotoxic drug-induced lung diseaseThe Treatment of Chronic Granulocytic LeukaemiaToxicity of Chemotherapeutic AgentsErythroleukemia-like syndrome due to busulfan toxicity in polycythemia veraChronic Granulocytic LeukemiaToxicity of Antineoplastic Agents in Man: Chromosomal Aberrations, Antifertility Effects, Congenital Malformations, and Carcinogenic PotentialMechanism of Action of MethanesulfonatesImmunosuppressive and Cytotoxic Chemotherapy: Long-Term ComplicationsPHILIP S. SCHEIN, M.D., F.A.C.P., M.R.C.P., STANLEY H. WINOKUR, M.D.BUSULPHAN LUNGCLINICAL AND MORPHOLOGICAL SIDE-EFFECTS OF BUSULFAN (MYLERAN) TREATMENTPitfalls in the diagnosis of metastatic carcinomaI. PodiumgesprächSOME EFFECTS OF ALKYLATING AGENTS ON EPITHELIA IN MAN AND IN AN EXPERIMENTAL SYSTEM IN THE RATInterstitial pulmonary fibrosis, atypical epithelial changes and bronchiolar cell carcinoma following busulfan therapyBusulphan lung"Selective" Pituitary Insufficiency Secondary to BusulfanRAYMOND J. VIVACQUA, M.D., FARID I. HAURANI, M.D., F.A.C.P., ALLAN J. ERSLEV, M.D., F.A.C.P.Hematologic Complexities 1 October 1965Volume 63, Issue 4Page: 654-660KeywordsDysplasiaHematology and oncologyHospital medicineHyperpigmentationLaboratory testsMedical servicesNauseaResearch facilitiesVomitingWeight loss ePublished: 1 December 2008 Issue Published: 1 October 1965 PDF downloadLoading ...